Medication Compliance and Persistence: Terminology and Definitions

DiMatteo, 2002, Patient adherence and medical treatment outcomes: a meta-analysis, Med Care, 40, 794, 10.1097/00005650-200209000-00009 Cramer, 1995, Partial medication compliance: the enigma in poor medical outcomes, Am J Manag Care, 1, 45 Zyczynski, 2000, Hypertension and current issues in compliance and patient outcomes, Curr Hypertens Rep, 2, 510, 10.1007/s11906-996-0034-7 Avorn, 1998, Persistence of use of lipid-lowering medications: cross-national study, JAMA, 279, 1458, 10.1001/jama.279.18.1458 Howell, 2004, Compliance with statins in primary care, Pharm J, 272, 1 Urquhart, 2000, Defining the margins for errors in patient compliance with prescribed drug regimens, Pharmacoepidemiol Drug, 9, 565, 10.1002/pds.540 Hasford, 1991, Biometric issues in measuring and analyzing partial compliance in clinical trials Feinstein, 1990, On white coat effects and the electronic monitoring of compliance, Arch Intern Med, 150, 1377, 10.1001/archinte.1990.00390190043003 Caro, 2004, The impact of compliance with osteoporosis therapy on fracture rates in actual practice, Osteoporos Int, 15, 1003, 10.1007/s00198-004-1652-z Sackett, 1976 Sabate, 2003 Cramer, 1995, Relationship between medication compliance and medical outcomes, Am J Health Syst Pharm, 52, S52 Lopatriello, 2004, Different aspects of adherence to antihypertensive treatments, Exp Rev Pharmacoeconom Res, 4, 317 Roter, 1998, Effectiveness of interventions to improve patient adherence: a metaanalysis, Med Care, 36, 1138, 10.1097/00005650-199808000-00004 Eisen, 1990, The effect of prescribed daily dose frequency on patient medication compliance, Arch Intern Med, 150, 1881, 10.1001/archinte.1990.00390200073014 Cramer, 1989, How often is medication taken as prescribed? A novel assessment technique, JAMA, 261, 3273, 10.1001/jama.1989.03420220087032 Claxton, 2001, Medication compliance: the importance of the dosing regimen, Clin Ther, 23, 1296, 10.1016/S0149-2918(01)80109-0 Catalan, 2000, Predictors of long term persistence on statins in a subsidized clinical population, Value Health, 3, 417, 10.1046/j.1524-4733.2000.36006.x Yanni, 2005, Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program, Value Health, 8, 495, 10.1111/j.1524-4733.2005.00041.x Cramer, 2005, Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis, Curr Med Res Opin, 21, 1453, 10.1185/030079905X61875 White, 2002, Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services, J Manag Care Pharm, 8, 186, 10.18553/jmcp.2002.8.3.186 Mauskopf, 2005, Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings, J Manag Care Pharm, 11, 231, 10.18553/jmcp.2005.11.3.231 Grant, 2004, Impact of concurrent medication use on statin adherence and refill persistence, Arch Intern Med, 164, 2343, 10.1001/archinte.164.21.2343 Cramer, 2004, Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate, Clin Ther, 26, 905, 10.1016/S0149-2918(04)90134-8 Malone, 2003, Pharmacist intervention enhances adherence to Orlistat therapy, Ann Pharmacother, 37, 1598, 10.1345/aph.1D183 Carswell, 2004, Tracking trends in secondary stroke prevention strategies, Ann Pharmacother, 38, 215, 10.1345/aph.1D190 Sikka, 2005, Estimating medication persistency using administrative claims data, Am J Manag Care, 11, 449 Steiner, 1997, The assessment of refill compliance using pharmacy records. Methods, validity, and applications, J Clin Epidemiol, 50, 105, 10.1016/S0895-4356(96)00268-5 Peterson, 2007, A checklist for medication compliance and persistence studies using retrospective databases, Value Health, 10, 3, 10.1111/j.1524-4733.2006.00139.x Burrell, 2005, Defining compliance/adherence and persistence: ISPOR Special Interest Working Group, Value Health, 8, A194, 10.1016/S1098-3015(10)67746-7